---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-085516"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:42:46.328365+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acrivon terminates Akoya/Quanterix diagnostic deal; opens internal CLIA lab

## Summary
- Mutually terminated OncoSignature Companion Diagnostic Agreement with Akoya (Quanterix) effective Feb 25, 2026.
- No financial payments between the parties for termination; transition plan transfers testing procedures and materials to Acrivon.
- Acrivon has completed and certified its own internal CLIA laboratory in Watertown, MA.
- Acrivon now has full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
- Quanterix will continue to support ACR-368 clinical testing for Acrivon's ongoing Phase 2b study during the transition.

## SEC filing metadata
- accession: 0001193125-26-085516
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/0001193125-26-085516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-085516
- JSON: https://secwatch.observer/filing/0001193125-26-085516.json
- Plain text: https://secwatch.observer/filing/0001193125-26-085516.txt

## Key facts
- Material Agreements
  Acrivon Therapeutics, Inc. terminated OncoSignature Companion Diagnostic Agreement with Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation) (effective 2026-02-25).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation)
  - Effective: 2026-02-25
  source text: On February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into a Termination and Transition Agreement pursuant to which they have mutually agreed to terminate (the “termination”) the OncoSignature Companion Diagnostic Agreement, dated June 17, 2022, by and between the Company and Akoya.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/0001193125-26-085516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.